-
SAB Biotherapeutics Awarded $27M Contract to Develop Novel Rapid Response Capability for U.S. Department of Defense
Sioux Falls, S.D., March 31, 2020 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, advancing a new class of immunotherapies…
-
SAB Biotherapeutics Delays Development At USD Discovery District
Sioux Falls, S.D., March 13, 2020 – SAB Biotherapeutics (SAB), an immunotherapy company that has harnessed the native immune response, announced today it…
-
SAB Biotherapeutics Announces Research Collaboration With CSL Behring
January 07, 2020 09:36 AM Eastern Standard Time SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical…
-
SAB Biotherapeutics Raises $22M In Series A-2 Round
December 20, 2018 02:35 PM Eastern Standard Time SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical…
-
South Dakota Equity Partners Invests $1.05M In SAB Biotherapeutics
December 28, 2018 Central Standard Time Sioux Falls, S.D.,– South Dakota Equity Partners (SDEP) today announced it has invested $1.05 million in SAB…
-
USD Discovery District Breaks Ground For First Building Project
SIOUX FALLS, S.D. – The USD Discovery District, an 80-acre corporate and academic research park in northwest Sioux Falls, held a groundbreaking today for…
-
Ebola Successfully Neutralized By Latest Generation Polyclonal Immunotherapy
Aug 15, 2018 6:37 p.m. Eastern Standard Time Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical…
-
USD Discovery District Announces Anchor Tenants For Innovation Community
June 4, 2018 The University of South Dakota Discovery District officials announced their first tenant on Monday. SAB Biotherapeutics, a clinical-stage…
-
SAB Biotherapeutics Expands VAC Team
Sioux Falls, S.D., – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, has expanded its Vaccinology and Antibody…
-
SAB Capra Awarded $225K From NIH To Broaden Novel Immunotherapy Platform
February 01, 2018 03:44 PM Eastern Standard Time SIOUX FALLS, S.D. & SALT LAKE CITY(BUSINESS WIRE)SAB Capra, LLC, a privately-held, emerging…
-
First Treatment For MERS Appears Safe In NIH Phase I Clinical Trial
Jan 10, 2018 3:49 p.m. ET Human polyclonal immunotherapy platform shows broad potential to combat infectious disease SIOUX FALLS, S.D., Jan 10, 2018…
-
First-In-Human Trial Of New Immunotherapy Approach Shows Efficacy In Antibiotic Resistance
Published: Dec 22, 2017 Human polyclonal antibodies show promise as effective treatment SIOUX FALLS, S.D.(BUSINESS WIRE) SAb Biotherapeutics, a…